Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Revive Therapeutics starts human trials for its cystinuria treatment

Tuesday, February 7, 2017 7:41
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Drug developer Revive Therapeutics Ltd. (CVE:RVV) has started treating the first patients in the phase II clinical study of its REV-004 cystinuria treatment.

Up to 30 patients with cystinuria – a genetic disease that causes kidney and bladder stones – will be treated with REV-004, or Bucillamine as it is also known, for seven days.

Patients will then be monitored for another seven days as a safety precaution.

The primary aim of the trial is to ass the safety and tolerability of the drug, while a secondary outcome will assess the excretion of cystine in the patients’ urine.

“The initiation of the phase II study marks another important clinical milestone for Revive,” says Fabio Chianelli, President of Revive.

“I am very excited to advance our cystinuria treatment into human clinical trials in the US, and we look forward to updating the investment and medical communities on our developments as they arise.”

The US Food & Drug Administration (FDA) accepted Revive’s investigational new drug application (IND) last summer which paved the way for the clinical trial.

The FDA also granted REV-004 orphan designation status as a treatment for cystinuria.

Cystinuria is a hereditary disease that causes high concentrations of the amino acid cysteine in the urine, which leads to the formation of cystine stones in the kidneys, ureter and bladder.

It is hoped that Bucillamine will mix with the cystine and lower the concentration to make the cystine soluble and prevent the formation of stones. This new soluble compound can then be excreted in the urine.

Revive shares closed at C$0.12 on Monday.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/172794/revive-therapeutics-starts-human-trials-for-its-cystinuria-treatment-172794.html

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.